+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats



Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats



Infection and Immunity 65(10): 4146-4151



The protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide (CP5) was examined in a modified model of catheter-induced endocarditis. Rats were catheterized by surgically passing a polyethylene catheter through the right carotid artery and aortic valve into the left ventricle. The following day, the rats were injected by the intraperitoneal (i.p.) route with immunoglobulin G (IgG) purified from nonimmunized rabbits or from rabbits immunized with a conjugate vaccine composed of CP5 and CP8 linked covalently to recombinant Pseudomonas aeruginosa exotoxoid A. One day after passive immunization, the animals were challenged i.p. with one of three serotype 5 S. aureus isolates (strain Reynolds, Lowenstein, or VP) or nontypeable strain 521. Protection was evaluated by comparing quantitative cultures of blood, endocardial vegetations, and kidneys from control and immune animals. For experiments performed with S. aureus Reynolds and Lowenstein, rats given capsular antibodies (645 microg of CP5-specific IgG) showed a significantly (P < 0.05) lower prevalence of endocarditis than rats injected with nonimmune IgG. Similarly, quantitative cultures of the blood, kidneys, and aortic valve vegetations revealed that fewer S. aureus cells were recovered from rats given capsule-specific IgG than from rats administered nonimmune IgG. Rats challenged with strain VP were protected with 1.145 mg of CP5-specific IgG. Capsular antibodies did not protect against infection elicited by a nontypeable strain. These results demonstrate that capsular antibodies elicited by immunization with a polysaccharide-protein conjugate vaccine protect experimental animals against serotype 5 S. aureus infection in a modified model of endocarditis.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 009265327

Download citation: RISBibTeXText

PMID: 9317020


Related references

Protective efficacy of antibodies to the type 5 capsular polysaccharide of Staphylococcus aureus in rat model of catheter-induced endocarditis. Abstracts of the General Meeting of the American Society for Microbiology 94: 154, 1994

Protective efficacy of antibodies to the Staphylococcus aureus capsular polysaccharide in a rat model of endocarditis. Abstracts of the General Meeting of the American Society for Microbiology 96: 211, 1996

Diagnosing Staphylococcus aureus endocarditis by detecting antibodies against S. aureus capsular polysaccharide types 5 and 8. Journal of Infectious Diseases 163(3): 530-533, 1991

Capsular polysaccharide antigenemia in rats with experimental endocarditis due to Staphylococcus aureus. Journal of Infectious Diseases 155(2): 242-246, 1987

Antibodies to capsular polysaccharides are not protective against experimental Staphylococcus aureus endocarditis. Infection and Immunity 63(2): 375-380, 1995

Capsular polysaccharide antibodies against Staphylococcus aureus Smith strain and protective ability postimmunization in rabbits. Annual meeting 7th) 339-340, 1998

Natural antibodies in normal human serum inhibit Staphylococcus aureus capsular polysaccharide vaccine efficacy. Clinical Infectious Diseases 55(9): 1188-1197, 2012

Production of bispecific antibodies to bovine polymorphonuclear neutrophils and to Staphylococcus aureus capsular polysaccharide type 5. Journal of Dairy Science 81(Suppl. 1): 37, 1998

Reactivity of type-specific monoclonal antibodies with Staphylococcus aureus clinical isolates and purified capsular polysaccharide. Infection and Immunity 49(1): 14-18, 1985

Regulation of Staphylococcus aureus type 5 capsular polysaccharides by agr and sarA in vitro and in an experimental endocarditis model. Microbial Pathogenesis 33(2): 73-79, 2002

The Production of Antibodies Directed Against Staphylococcus aureus Serotype 8 Capsular Polysaccharide. FASEB Journal 18(4-5): Abst 554 33, 2004

Isolation of type 5 capsular polysaccharide from Staphylococcus aureus. Annales de l'Institut Pasteur. Microbiology 138(5): 561-567, 1987

Structure of the type 5 capsular polysaccharide of Staphylococcus aureus. Carbohydrate Research 201(2): 285-297, 1990

The role of the capsular polysaccharide adhesin virulence and immunoprophylaxis of S aureus endocarditis in rats. Abstracts of the General Meeting of the American Society for Microbiology 101: 284, 2001

Capsular antigens of Staphylococcus aureus. I. Further purification of the capsular antigen of a major capsular type of Staphylococcus aureus. Canadian Journal of Microbiology 18(8): 1283-1288, 1972